Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia.

Trial Profile

Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PERTAIN
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 17 Jun 2009 Planned number of patients changed from 294 to 294 as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top